What is HC Wainwright’s Forecast for VRDN FY2026 Earnings?

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – HC Wainwright upped their FY2026 EPS estimates for shares of Viridian Therapeutics in a research note issued on Thursday, November 5th. HC Wainwright analyst D. Tsao now expects that the company will earn ($3.58) per share for the year, up from their prior estimate of ($4.28). HC Wainwright has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($3.64) per share. HC Wainwright also issued estimates for Viridian Therapeutics’ Q4 2026 earnings at ($0.82) EPS, Q1 2027 earnings at ($0.77) EPS, Q2 2027 earnings at ($0.77) EPS, Q3 2027 earnings at ($0.76) EPS, FY2027 earnings at ($2.45) EPS, FY2028 earnings at ($1.09) EPS, FY2029 earnings at $1.26 EPS and FY2030 earnings at $4.14 EPS.

Other research analysts have also recently issued research reports about the company. Truist Financial upped their price target on Viridian Therapeutics from $39.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, November 5th. Wall Street Zen raised Viridian Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings upgraded Viridian Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, September 14th. Wells Fargo & Company lifted their target price on Viridian Therapeutics from $31.00 to $34.00 and gave the stock an “overweight” rating in a report on Thursday, November 5th. Finally, Royal Bank Of Canada boosted their target price on Viridian Therapeutics from $38.00 to $41.00 and gave the stock an “outperform” rating in a research report on Thursday, November 5th. Eleven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $41.00.

Viridian Therapeutics Trading Up 6.0%

Shares of NASDAQ:VRDN opened at $30.19 on Monday. The stock has a market capitalization of $3.42 billion, a price-to-earnings ratio of -7.86 and a beta of 1.07. Viridian Therapeutics has a 1-year low of $13.18 and a 1-year high of $34.29. The company has a debt-to-equity ratio of 0.43, a quick ratio of 16.95 and a current ratio of 16.95. The company has a 50 day moving average price of $22.12 and a 200 day moving average price of $21.80.

Viridian Therapeutics (NASDAQ:VRDN) last released its earnings results on Wednesday, November 4th. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.21. Viridian Therapeutics had a negative net margin of 1,620.79% and a negative return on equity of 77.15%. The business had revenue of $25.75 million for the quarter, compared to the consensus estimate of $4.72 million.

Insiders Place Their Bets

In related news, insider Jennifer Tousignant sold 14,212 shares of the stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $24.50, for a total value of $348,194.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Viridian Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Wellington Management Group LLP increased its holdings in shares of Viridian Therapeutics by 1.6% in the 2nd quarter. Wellington Management Group LLP now owns 3,128,362 shares of the company’s stock valued at $57,468,000 after purchasing an additional 49,808 shares during the period. Parkman Healthcare Partners LLC acquired a new stake in shares of Viridian Therapeutics during the second quarter worth approximately $25,306,000. Rice Hall James & Associates LLC purchased a new position in Viridian Therapeutics during the second quarter valued at approximately $21,601,000. Bank of America Corp DE grew its position in Viridian Therapeutics by 17.5% during the first quarter. Bank of America Corp DE now owns 1,163,615 shares of the company’s stock valued at $22,760,000 after purchasing an additional 173,498 shares in the last quarter. Finally, Elmind Capital LP purchased a new position in Viridian Therapeutics during the second quarter valued at approximately $18,093,182.

Viridian Therapeutics Company Profile

Viridian Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious diseases, with a primary focus on thyroid eye disease (TED), an autoimmune condition that can cause inflammation and changes around the eyes.

The company’s pipeline includes veligrotug, an investigational antibody that targets the insulin-like growth factor 1 receptor, a pathway involved in TED. Viridian is also developing additional antibody-based candidates intended to offer treatment options, including formulations designed for under-the-skin administration.